康辰药业
(603590)
| 流通市值：79.90亿 | | | 总市值：80.48亿 |
| 流通股本：1.58亿 | | | 总股本：1.59亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 692,220,405.14 | 460,869,253.77 | 212,002,399.05 | 825,397,797.2 |
| 营业收入 | 692,220,405.14 | 460,869,253.77 | 212,002,399.05 | 825,397,797.2 |
| 二、营业总成本 | 534,795,468.49 | 340,875,691.38 | 152,416,687.23 | 696,236,061.61 |
| 营业成本 | 68,161,056.22 | 45,249,089.13 | 20,909,945.62 | 86,125,361.11 |
| 税金及附加 | 7,751,201.78 | 4,496,497.65 | 1,222,007.45 | 6,745,994.41 |
| 销售费用 | 326,641,391.08 | 204,384,553.16 | 90,013,005.63 | 418,444,627.71 |
| 管理费用 | 99,101,178.46 | 66,697,905.34 | 32,879,012.54 | 135,311,648.72 |
| 研发费用 | 32,800,011.37 | 20,498,356.48 | 8,078,499.71 | 54,937,808.73 |
| 财务费用 | 340,629.58 | -450,710.38 | -685,783.72 | -5,329,379.07 |
| 其中:利息费用 | 5,404,523.56 | 3,325,291.61 | 1,936,052.73 | 6,155,499.15 |
| 其中:利息收入 | 7,449,849.16 | 5,514,212.27 | 3,393,168.72 | 12,833,810.36 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 804,230.25 | 379,689.56 | -122,989.78 | -486,686.56 |
| 加:投资收益 | 9,270,027.04 | 10,015,947.42 | 540,637.31 | 18,142,328.06 |
| 资产处置收益 | 130,668.15 | 130,668.15 | 88,495.58 | -7,331.58 |
| 资产减值损失(新) | - | - | - | -105,547,311.98 |
| 信用减值损失(新) | -10,611,214.32 | -12,339,386.46 | -4,578,317.13 | -6,423,851.6 |
| 其他收益 | 4,243,921.46 | 3,011,768.87 | 1,338,860.01 | 4,248,923.24 |
| 四、营业利润 | 161,262,569.23 | 121,192,249.93 | 56,852,397.81 | 39,087,805.17 |
| 加:营业外收入 | 20,306.74 | 12,764.34 | 10,231.9 | 2,630.45 |
| 减:营业外支出 | 13,071,584.05 | 11,437,127.01 | 1,312,269.8 | 226,688.07 |
| 五、利润总额 | 148,211,291.92 | 109,767,887.26 | 55,550,359.91 | 38,863,747.55 |
| 减:所得税费用 | 13,908,706.93 | 13,433,248.07 | 7,412,809.54 | 17,333,203 |
| 六、净利润 | 134,302,584.99 | 96,334,639.19 | 48,137,550.37 | 21,530,544.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 134,302,584.99 | 96,334,639.19 | 48,137,550.37 | 21,530,544.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 127,880,071.73 | 91,046,083.02 | 44,497,393.8 | 42,216,726.62 |
| 少数股东损益 | 6,422,513.26 | 5,288,556.17 | 3,640,156.57 | -20,686,182.07 |
| 扣除非经常损益后的净利润 | 133,026,315.24 | 96,257,444.5 | 43,899,622.52 | 31,076,778.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.81 | 0.58 | 0.28 | 0.27 |
| (二)稀释每股收益 | 0.81 | 0.58 | 0.28 | 0.27 |
| 八、其他综合收益 | -48,898,274.85 | -44,025,848.89 | -38,283,346.86 | 58,297,183.27 |
| 归属于母公司股东的其他综合收益 | -48,898,274.85 | -44,025,848.89 | -38,283,346.86 | 58,297,183.27 |
| 九、综合收益总额 | 85,404,310.14 | 52,308,790.3 | 9,854,203.51 | 79,827,727.82 |
| 归属于母公司股东的综合收益总额 | 78,981,796.88 | 47,020,234.13 | 6,214,046.94 | 100,513,909.89 |
| 归属于少数股东的综合收益总额 | 6,422,513.26 | 5,288,556.17 | 3,640,156.57 | -20,686,182.07 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |